Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial by Hans Salwender, Niels Weinhold, Axel Benner, Kaya Miah, Maximilian Merz, Mathias Haenel, Christian Jehn, Elias Mai, Ekaterina Menis, Igor Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Steffen Luntz, Britta Besemer, Markus Munder, Peter Brossart, Bertram Glass, Hans-Walter Lindemann, Katja Weisel, Christine Hanoun, Paul Schnitzler, Sarah Klemm, Hartmut Goldschmidt, Marc Raab, Ahmet Elmaagacli

Get full text

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy by Maximilian Merz, Danai Dima, Hamza Hashmi, Nausheen Ahmed, Friedrich Stölzel, Tobias A. W. Holderried, Roland Fenk, Fabian Müller, Natalia Tovar, Aina Oliver-Cáldes, Kristin Rathje, James A. Davis, David Fandrei, Vladan Vucinic, Soraya Kharboutli, Ben-Niklas Baermann, Francis Ayuk, Uwe Platzbecker, Anca-Maria Albici, Nathalie Schub, Friederike Schmitz, Leyla Shune, Jack Khouri, Faiz Anwer, Shahzad Raza, Joseph McGuirk, Zahra Mahmoudjafari, Kimberly Green, Cyrus Khandanpour, Marcel Teichert, Barbara Jeker, Michele Hoffmann, Nicolaus Kröger, Bastian von Tresckow, Carlos Fernández de Larrea, Thomas Pabst, Al-Ola Abdallah, Nico Gagelmann

Get full text